Searchable News & Info From Reliable Online Sources.
- Sleep patterns could predict risk for dementia, cancer and stroke, study suggests
New developments in artificial intelligence could use sleep data to predict disease risk, a new study suggests.Stanford Medicine researchers have developed an AI model trained on nearly 600,000 hours of sleep data collected from over 60,000 participants at various sleep clinics.The model, called SleepFM, reportedly can predict a person’s risk of developing more than 100 health conditions, according to a press release from the university.ALZHEIMER'S RISK COULD RISE WITH COMMON CONDITION AFFECTING MILLIONS, STUDY FINDSThe researchers trained SleepFM using polysomnography, a comprehensive sleep measurement that tracks brain and heart activity as well as breathing, leg movements and eye movements. It is considered the "gold standard" of sleep studies, they noted."Sleep contains far more information about future health than we currently use," James Zou, Ph.D., associate professor of biomedical data science and co-senior author of the study, told Fox News Digital."By learning the language of sleep, our AI model opens new doors… ...[TheTopNews] Read More.29 mins ago - Boy with flu spent three weeks in intensive care
His family is urging other parents to ensure their children are vaccinated against the virus. ...[TheTopNews] Read More.6 hours ago - Safe spaces needed for drug-addicted children, say grieving mumsMore children in England are in drug and alcohol treatment, but families say many cannot get help. ...[TheTopNews] Read More.11 hours ago
- I spent months investigating whether gut health affects ageing – and if I could hack my own gu...Health editor Hugh Pym revamped his diet after a test suggested his gut health appeared to look five years older than he was ...[TheTopNews] Read More.12 hours ago
- Researchers locked flu patients in a hotel with healthy adults — no one got sickWith an aggressive new strain spreading across the country, this year’s flu season has been marked by record-high hospitalizations and reportedly intense symptoms.As people look for ways to contain the spread, new research has found that a few simple factors can greatly reduce transmission.Researchers from the University of Maryland Schools of Public Health and Engineering in College Park and the School of Medicine in Baltimore studied influenza spread by placing flu-positive college students in a hotel room with healthy middle-aged adult volunteers.FLU HOSPITALIZATIONS HIT ALL-TIME WEEKLY HIGH IN DENSELY POPULATED STATE, OFFICIALS WARNThe study, published in the journal PLOS Pathogens, is reportedly the first clinical trial investigating how the flu spreads from naturally infected people to uninfected people, according to a press release.The participants, including 11 healthy volunteers, lived on a quarantined floor of a Baltimore-area hotel for two weeks. During that time, they simulated interactions, including having conversations, doing… ...[TheTopNews] Read More.16 hours ago
- Are there ‘forever chemicals’ in your raincoat?Could your skin be absorbing PFAS (Perfluoroalkyl and Polyfluoroalkyl Substances), also known as 'forever chemicals' through your raincoat? ...[TheTopNews] Read More.19 hours ago
- Relearning to walk and talk after a brain tumourEkam Dhaliwal discusses his experience following brain tumour surgery. ...[TheTopNews] Read More.22 hours ago
- What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredientsGLP-1 has become a popular buzzword in the weight-loss community — but now some are touting "GLP-3s," claiming they are taking obesity medications to the next level.GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite.The informal term "GLP-3" refers to a new triple-agonist drug that targets three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide, another naturally occurring hormone released by the gut after eating) and glucagon receptors. The most advanced example is retatrutide by Eli Lilly, according to clinical trial outcomes.OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOUThe New England Journal of Medicine published results from a 2023 phase 2 retatrutide trial for obesity, revealing "substantial reductions in body weight" after 48 weeks of treatment.A 12 mg once-weekly injection led to a 24.2% weight reduction, and participants continued to drop pounds after the… ...[TheTopNews] Read More.1 day ago
The Searchable USWebDaily.com and TheTopNews NewsBank Helps You Be Better Informed, Faster! Spread The Word.
